Cargando…
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
BACKGROUND: Primary myelofibrosis (PMF) is a type of myeloproliferative neoplasm (MPN) characterized by the predominant proliferation of megakaryocytes and granulocytes in the bone marrow, leading to the deposition of fibrous tissue, and by a propensity toward extramedullary hematopoiesis. Renal inv...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521341/ https://www.ncbi.nlm.nih.gov/pubmed/26232031 http://dx.doi.org/10.1186/s12882-015-0121-6 |
_version_ | 1782383799267491840 |
---|---|
author | Rajasekaran, Arun Ngo, Thuy-Trang Abdelrahim, Maen Glass, William Podoll, Amber Verstovsek, Srdan Abudayyeh, Ala |
author_facet | Rajasekaran, Arun Ngo, Thuy-Trang Abdelrahim, Maen Glass, William Podoll, Amber Verstovsek, Srdan Abudayyeh, Ala |
author_sort | Rajasekaran, Arun |
collection | PubMed |
description | BACKGROUND: Primary myelofibrosis (PMF) is a type of myeloproliferative neoplasm (MPN) characterized by the predominant proliferation of megakaryocytes and granulocytes in the bone marrow, leading to the deposition of fibrous tissue, and by a propensity toward extramedullary hematopoiesis. Renal involvement in PMF is rare, but kidney tissue samples from these patients reveal MPN-related glomerulopathy, a recently discovered condition, in the late stages of the disease. CASE PRESENTATION: We present the first case described in the medical literature of a patient with early renal glomerular involvement in PMF/MPN. A 60-year-old man with stage 4 chronic kidney disease and a recent diagnosis of PMF (within 4 weeks of presentation at our renal division) presented with generalized body swelling, acute kidney injury, and massive nephrotic-range proteinuria. Kidney biopsy was performed to determine the etiology of the patient’s renal dysfunction and revealed early renal glomerular involvement that was histologically characteristic of MPN-related glomerulopathy. Early diagnosis and prompt medical management returned the patient’s kidney functionality to the levels seen on initial presentation at our hospital. CONCLUSION: Large studies with long follow-up durations are necessary to identify and categorize the risk factors for the development of MPN-related glomerulopathy, to standardize therapeutic regimens, and to determine whether aggressive management of the myelofibrosis slows the progression of kidney disease. |
format | Online Article Text |
id | pubmed-4521341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45213412015-08-01 Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib Rajasekaran, Arun Ngo, Thuy-Trang Abdelrahim, Maen Glass, William Podoll, Amber Verstovsek, Srdan Abudayyeh, Ala BMC Nephrol Case Report BACKGROUND: Primary myelofibrosis (PMF) is a type of myeloproliferative neoplasm (MPN) characterized by the predominant proliferation of megakaryocytes and granulocytes in the bone marrow, leading to the deposition of fibrous tissue, and by a propensity toward extramedullary hematopoiesis. Renal involvement in PMF is rare, but kidney tissue samples from these patients reveal MPN-related glomerulopathy, a recently discovered condition, in the late stages of the disease. CASE PRESENTATION: We present the first case described in the medical literature of a patient with early renal glomerular involvement in PMF/MPN. A 60-year-old man with stage 4 chronic kidney disease and a recent diagnosis of PMF (within 4 weeks of presentation at our renal division) presented with generalized body swelling, acute kidney injury, and massive nephrotic-range proteinuria. Kidney biopsy was performed to determine the etiology of the patient’s renal dysfunction and revealed early renal glomerular involvement that was histologically characteristic of MPN-related glomerulopathy. Early diagnosis and prompt medical management returned the patient’s kidney functionality to the levels seen on initial presentation at our hospital. CONCLUSION: Large studies with long follow-up durations are necessary to identify and categorize the risk factors for the development of MPN-related glomerulopathy, to standardize therapeutic regimens, and to determine whether aggressive management of the myelofibrosis slows the progression of kidney disease. BioMed Central 2015-08-01 /pmc/articles/PMC4521341/ /pubmed/26232031 http://dx.doi.org/10.1186/s12882-015-0121-6 Text en © Rajasekaran et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Rajasekaran, Arun Ngo, Thuy-Trang Abdelrahim, Maen Glass, William Podoll, Amber Verstovsek, Srdan Abudayyeh, Ala Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib |
title | Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib |
title_full | Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib |
title_fullStr | Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib |
title_full_unstemmed | Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib |
title_short | Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib |
title_sort | primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521341/ https://www.ncbi.nlm.nih.gov/pubmed/26232031 http://dx.doi.org/10.1186/s12882-015-0121-6 |
work_keys_str_mv | AT rajasekaranarun primarymyelofibrosisassociatedglomerulopathysignificantimprovementaftertherapywithruxolitinib AT ngothuytrang primarymyelofibrosisassociatedglomerulopathysignificantimprovementaftertherapywithruxolitinib AT abdelrahimmaen primarymyelofibrosisassociatedglomerulopathysignificantimprovementaftertherapywithruxolitinib AT glasswilliam primarymyelofibrosisassociatedglomerulopathysignificantimprovementaftertherapywithruxolitinib AT podollamber primarymyelofibrosisassociatedglomerulopathysignificantimprovementaftertherapywithruxolitinib AT verstovseksrdan primarymyelofibrosisassociatedglomerulopathysignificantimprovementaftertherapywithruxolitinib AT abudayyehala primarymyelofibrosisassociatedglomerulopathysignificantimprovementaftertherapywithruxolitinib |